A61P 13/08
Drugs for disorders of the urinary system: of the prostate
Official title: of the prostate
A61P13/08 (Drugs for disorders of the urinary system: of the prostate) appears on 4,815 US grants and 7,277 published applications in this corpus.
Search patents in A61P- Granted patents
- 4,815
- Published applications
- 7,277
- Assignees
- 2,047
- Inventors
- 11,799
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 4 | 0 |
| 1994 | 5 | 0 |
| 1995 | 5 | 0 |
| 1996 | 11 | 0 |
| 1997 | 13 | 0 |
| 1998 | 26 | 0 |
| 1999 | 46 | 0 |
| 2000 | 65 | 0 |
| 2001 | 95 | 34 |
| 2002 | 90 | 139 |
| 2003 | 91 | 252 |
| 2004 | 99 | 346 |
| 2005 | 114 | 353 |
| 2006 | 163 | 319 |
| 2007 | 160 | 358 |
| 2008 | 149 | 391 |
| 2009 | 190 | 457 |
| 2010 | 248 | 489 |
| 2011 | 260 | 410 |
| 2012 | 308 | 391 |
| 2013 | 331 | 370 |
| 2014 | 342 | 420 |
| 2015 | 273 | 360 |
| 2016 | 273 | 392 |
| 2017 | 273 | 357 |
| 2018 | 245 | 311 |
| 2019 | 235 | 251 |
| 2020 | 217 | 226 |
| 2021 | 117 | 155 |
| 2022 | 105 | 144 |
| 2023 | 84 | 135 |
| 2024 | 78 | 89 |
| 2025 | 61 | 89 |
| 2026 | 39 | 39 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods comprising endothelin a receptor antagonists and androgen therapies29 Sep 2026US 12,746,239 B2The United States Government as represented by the Department of Veterans Affairs
- Treatment of prostate cancer with a combination of abiraterone acetate, niraparib tosylate monohydrate and prednisone15 Sep 2026US 12,734,180 B2Janssen Pharmaceutica NV
- Application of stachyose in preparation of drug for treating castration-resistant prostate cancer21 Jul 2026US 12,685,742 B2Jiangnan University
- Compounds, compositions, methods, and uses for treating cancer and immunological disorders7 Jul 2026US 12,673,109 B2Il-2Rx
- Composition for preventing, improving or treating benign prostatic hyperplasia or alopecia, comprising heat-killed probiotics as active ingredient30 Jun 2026US 12,667,595 B2Bereum Co., Ltd
- Combination of anti-cdh6 antibody-drug conjugate and hif-2alpha inhibitor27 Aug 2026US 2026/0248938 A1Daiichi Sankyo Company, Limited
- Methods for treating igg4-related diseases27 Aug 2026US 2026/0250393 A1Xencor, Inc.
- Composition comprising recombinant clostridium neurotoxin20 Aug 2026US 2026/0240963 A1Ipsen Bioinnovation Limited
- Chimeric antigen receptors targeted to psca20 Aug 2026US 2026/0242509 A1City of Hope
- Methods of Selecting T Cell Line and Donor Thereof for Adoptive Cellular Therapy13 Aug 2026US 2026/0232793 A1Memorial Sloan Kettering Cancer Center
Most cited
By later US patents
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions616US 6,569,463 B2Lipocine Inc. · 2003
- Inhibitors of bruton's tyrosine kinase306US 7,514,444 B2Pharmacyclics, Inc. · 2009
- Human CTLA-4 antibodies300US 6,984,720 B1Medarex, Inc. · 2006